Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

04/20/2012 | 08:16pm US/Eastern

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

XIANYANG, China, April 20, 2012/PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in Chinafor a variety of diseases and conditions, today announced that it has received written notification from the Nasdaq Listing Qualifications department that it has regained compliance with the minimum bid price requirement of $1.00per share for continued listing of its common stock on The NASDAQ Global Market set forth in Nasdaq Listing Rule 5450(a)(1), as its common shares achieved a closing bid price of $1.00or more for 10 consecutive business days prior to the compliance deadline of April 23, 2012and this matter is now closed.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to maintain its ongoing compliance with the Nasdaq continued listing requirements, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:




BioStar Pharmaceuticals, Inc. 

The Equity Group, Inc.

Zack Pan, CFO 

Lena Cati

Tel: 405-996-8829 

Tel: 212 836-9611

Email: zpan@aoxing-group.com

Email: lcati@equityny.com

SOURCE Biostar Pharmaceuticals, Inc.

distributed by
React to this article
Latest news
Date Title
07:39a MAHINDRA & MAHINDRA : M&m drives in new age xuv500
07:39a CHENNAI PETROLEUM : Cpcl's preference shares to indian oil
07:39a CANARA BANK : Q4 profit flat as interest income dips
07:39a Anz bank to open rural branch near bengaluru next year
07:39a IN F : Nse's security lending scheme starts today
07:39a CRISIL : Vbhc value homes gets crisil ratings
07:39a VA TECH WABAG : Maintains profit in q4
07:39a JSW STEEL : Output up 2% in apr 2015
07:39a MICROSOFT : Hitachi solutions to expand
07:39a VANGUARD NATURAL RESOURCES : Other Events (form 8-K)
Latest news
Advertisement
Hot News 
CATALYST MEDIA : Announcement by SIS
STARCOM : Notification of Major Interest in Shares
EDEN RESEARCH : EU Product Authorisations
CTRIP : Announces Additional Investment by The Priceline Group
FLOWGROUP : Loss Widens As Sales Grow, But 2015 Will Be "Game-Changer"
Most Read News
06:44a Charter to buy Time Warner Cable in $78.7 billion deal
05/25 BARAKAH OFFSHORE PETROLEUM BHD : PBJV secures Shell jobs
01:43a ROYAL DUTCH SHELL A : PRESS: Decades Before Shell's Arctic Production Comes On Stream - FT
05/25 AUSTRALIA AND NEW ZEALAND BANKING : ANZ and ETF Securities launch joint venture with six ASX listed exchange traded funds
05/25 TIME WARNER : running out for Greece, ESM head Regling says
Most recommended articles
07:38a Futures lower ahead of raft of data
07:37aDJBELLE : Full-Year Net Profit CNY4.76 Billion
07:34a Futures point to lower start as oil slips
07:33aDJTATA MOTORS : Profit More Than Halved Last Quarter
07:31a UK might tighten bank capital rules as economy peaks - BoE's Taylor